Space startup Varda raises $187 million in funding to make drugs in orbit

Space startup Varda raises 7 million in funding to make drugs in orbit


Pavlo Gonchar | Lightrocket | Getty Images

Space startup Varda announced on Thursday that it has raised $187 million in Series C funding, led by venture capital firms Natural Capital and Shrug Capital, to continue advancing drug manufacturing in space.

The latest round included participation from Peter Thiel, Lux Capital, Khosla Ventures and Caffeinated Capital. It brought the total capital Varda’s raised to $329 million.

“By expanding, we can support work on more complex molecules and ultimately increase cadence to achieve the turnaround times the pharmaceutical industry expects,” Chief Science Officer Adrian Radocea said in a press release Thursday.

Varda’s main mission is to launch and return drugs made in space. The startup has said the medicines crystallize differently in orbit due to the gravity differences, which would allow it to complete drugs that are currently difficult to manufacture.

In 2024, the space startup’s W-Series 1 capsule received FAA approval to return after successfully creating the drug Ritonavir the previous year.

So far, Varda said the company has been able to complete three space launches. Now, a fourth is in orbit, and the company expects to launch a fifth by the end of the year. Varda’s system uses Rocket Lab’s Photon spacecraft for its operation and adds its manufacturing module and a heatshield-protected capsule.

“With this capital, Varda will continue to increase our flight cadence and build out the pharmaceutical lab that will deliver the world’s first microgravity-enabled drug formulation,” said Varda CEO Will Bruey.

Varda Space Industries is the first company to process materials outside the International Space Station.

Recently, the space company has also operated a testbed for the U.S. government to use the W-series reentry vehicles to advance technology.

Varda said it has expanded into Huntsville, Alaska, and opened a laboratory in El Segundo, California, to begin work to crystallize more drugs.

“Our new lab space is an investment in our belief that in-space pharmaceutical manufacturing will drive the foundation of the orbital economy,” Radocea said.



Source

Warner Bros. Discovery books .9 billion net loss tied to Paramount deal, restructuring costs
Business

Warner Bros. Discovery books $2.9 billion net loss tied to Paramount deal, restructuring costs

An American flag flies at Warner Bros. Studio in Burbank, California, on Sept. 12, 2025. Mario Tama | Getty Images Warner Bros. Discovery on Wednesday reported a staggering net loss for the first quarter, but it has an explanation. The company booked a net loss of $2.9 billion, far larger than the net loss of […]

Read More
FanDuel CEO Amy Howe is out after five years at the sportsbook
Business

FanDuel CEO Amy Howe is out after five years at the sportsbook

FanDuel CEO Amy Howe has been ousted from that post after five years at the company, people familiar with the matter told CNBC. Christian Genetski, FanDuel president, will step in to lead the company, according to the people, who asked not to be named in order to speak about internal matters. Howe, head of the […]

Read More
Novo Nordisk CEO says the drugmaker is more active than ever in seeking out deals
Business

Novo Nordisk CEO says the drugmaker is more active than ever in seeking out deals

Novo Nordisk is looking for deals more than ever before, the CEO of the Danish drugmaker said in an interview with CNBC on Wednesday. “If our ambition is to help hundreds of millions of patients out there, then we need not just the best, but the broadest pipeline in the world,” said Novo Nordisk CEO […]

Read More